Our perspective on the need for re-prioritization of outcomes in oncology. #Cancer nature.com/articles/s4301…

KayoThera will graduate from the Endless Frontier Labs Accelerator and will be presenting May 6th. kayothera.com/kayothera-to-g…

We're proud to announce, on our 50th anniversary, the launch of the Ludwig Princeton Branch. This new Branch is dedicated to the study of cancer metabolism & development of new paradigms for cancer prevention & treatment on the basis of those discoveries. bit.ly/32bJjs4

Please join us in congratulating 16 outstanding Life Sciences startup companies and their founders for graduating from the Endless Frontier Labs 2020-2021 program! These companies are harnessing the power of chemistry, biology, and computing to tackle global health challenges!

Kayothera is honored to be selected as the BIO 2021 Start-up Stadium Winner from a group of 16 innovative finalists during BIO Digital in June. #Cancer bio.org/press-release/…

The Life Sciences track at EFL is best suited for startups tackling complex problems in biology, chemistry or related fields with applications in therapeutics, drug discovery, drug design, delivery, diagnostics, and other health-focused verticals. Apply by Aug 6th!

Excited to announce our Series A round, lead by Accelerator Life Science Partners with participation from BioAdvance and 7G Bioventures! We are looking forward to improving cancer care with our first-in-class immunotherapies. businesswire.com/news/home/2022…

Kayothera founder Dr. Esposito was honored with Princeton University's Tiger #Entrepreneur Award during this year's Engage event! kayothera.com/kayothera-foun…

CMSGov guidance did not respond to patient, innovator & investor concerns about #IRA's core flaw: the small molecule 9-13 penalty that disincentivizes new & incremental R&D in lower copay, easy to take pills. Pls sign/share No Patient Left Behind call to action (1/3): nopatientleftbehind.docsend.com/view/u67bic7m9…

With the additional financial resources announced today, we are well-positioned to advance our lead diabetes and oncology programs, each of which has first-in-class potential in disease indications with large patient populations and significant unmet... businesswire.com/news/home/2023…

What no one has yet recognized about Biosecurity is that Americans won't care about who invents or doesn't invent new medicines if they don't think they will be able to afford them anyways. rapport.bio/all-stories/us… We need pro-AFFORDABLE innovation policy, not just

Honored to chair the Scientific Advisory Board at ⁦Kayothera⁩ alongside such talented colleagues! Together, we are advancing Kayothera's groundbreaking medicines for diabetes, obesity, and cancer. kayothera.com/kayothera-anno…

"The risky path might not be as risky as you thought compared to other options..." Interview of Nick Ouzounov *15, MolBio grad alum and co-founder of Geltor, makers of biodesigned proteins and polypeptides. Leading-up to Many Minds, Many Stripes conference molbio.princeton.edu/news/2025/nick…

“Policy is ultimately about people, and scientists need to be in those rooms helping shape it from the start.” Interview of MolBio grad alum and policy expert Ali Nouri *06 Dr. Ali Nouri, leading up to @PrincetonAlumni Many Minds, Many Stripes conference. molbio.princeton.edu/news/2025/ali-…

The item with the longest shelf-life in biology isn’t that moldy petri dish with your master cloning plasmid – it’s your last first author paper from graduate school that hasn’t been submitted yet. Today, that expires for Kayothera founder Dr. Esposito! cell.com/iscience/fullt…